Novavax, Inc. Share Price Nasdaq
Stocks
US6700021040
Biotechnology & Medical Research
| Market Cap | 178.31Cr 157.02Cr 148.77Cr 134.31Cr 253.13Cr 17TCr 256.4Cr 1.78TCr 684.96Cr 8.74TCr 669.54Cr 654.94Cr 28TCr | P/E 2026 * |
-17.3x | P/E 2027 * | -48.2x |
|---|---|---|---|---|---|
| Enterprise Value | 200.21Cr 176.3Cr 167.04Cr 150.8Cr 284.22Cr 19TCr 287.9Cr 2TCr 769.09Cr 9.81TCr 751.77Cr 735.38Cr 31TCr | EV / Sales 2026 * |
5.37x | EV / Sales 2027 * | 7.84x |
| Free-Float |
93.03% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Novavax, Inc.
| 1 day | -12.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 59 | 23/01/2023 |
James Kelly
DFI | Director of Finance/CFO | 60 | 16/08/2021 |
Robert Walker
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Douglas
BRD | Director/Board Member | 73 | 06/08/2010 |
Rachel King
BRD | Director/Board Member | 66 | 01/11/2018 |
David Mott
BRD | Director/Board Member | 60 | 16/06/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.33% | +1,148.37% | - | - | 178.31Cr | |
| +4.16% | -0.36% | +49.37% | +94.17% | 7.45TCr | |
| +0.40% | +1.75% | +28.42% | +81.88% | 6.01TCr | |
| -0.38% | +0.35% | +7.00% | +36.03% | 4.82TCr | |
| -0.05% | +0.37% | +41.54% | +36.65% | 4.43TCr | |
| +0.38% | +7.61% | +339.53% | +641.55% | 4.4TCr | |
| +0.18% | +0.26% | +7.41% | +103.45% | 4.16TCr | |
| -0.67% | +0.17% | +7.60% | +46.37% | 3TCr | |
| +4.77% | +6.16% | +36.77% | +22.78% | 2.93TCr | |
| -1.29% | -3.55% | -20.74% | +352.04% | 2.49TCr | |
| Average | -0.43% | +1.53% | +55.21% | +157.21% | 4.41TCr | |
| Weighted average by Cap. | +1.07% | +1.53% | +59.46% | +147.82% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37Cr 33Cr 31Cr 28Cr 53Cr 3.58TCr 54Cr 372.29Cr 143.27Cr 1.83TCr 140.04Cr 136.99Cr 5.86TCr | 27Cr 23Cr 22Cr 20Cr 38Cr 2.55TCr 38Cr 265.71Cr 102.25Cr 1.3TCr 100Cr 98Cr 4.18TCr |
| Net income | -11Cr -9.47Cr -8.97Cr -8.1Cr -15Cr -1.03TCr -15Cr -107.36Cr -41Cr -527.16Cr -40Cr -40Cr -1.69TCr | -3.79Cr -3.34Cr -3.16Cr -2.86Cr -5.38Cr -363.66Cr -5.45Cr -38Cr -15Cr -185.91Cr -14Cr -14Cr -596.03Cr |
| Net Debt | 22Cr 19Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 218.61Cr 84Cr 1.07TCr 82Cr 80Cr 3.44TCr | 30Cr 27Cr 25Cr 23Cr 43Cr 2.91TCr 44Cr 302.68Cr 116.48Cr 1.49TCr 113.86Cr 111.37Cr 4.77TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
